Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized study of oral valganciclovir versus intravenous ganciclovir for preemptive CMV therapy after stem cell transplantation
2010-020551-31Phase 4Completed
- Sponsor
- Nordic Bone Marrow Transplantation Group
- Start
- May 2010
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in cytomegalovirus disease (CMV) comparing Oral valganciclovir with Intravenous ganciclovir (2 arms). Primary endpoint: CMV PCR negativity by day 28. Started May 2010; status: completed.
02
Drugs
valganciclovirganciclovir
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on 2010-020551-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020551-31.